Menu
Search
|

Menu

Close
X

Inflarx NV IFRX.OQ (NASDAQ Stock Exchange Global Select Market)

28.60 USD
+0.16 (+0.56%)
As of 3:24 PM GMT
chart
Previous Close 28.44
Open 28.02
Volume 308
3m Avg Volume 6,851
Today’s High 28.60
Today’s Low 28.02
52 Week High 42.79
52 Week Low 14.55
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, EUR)
FY18
0
FY17
0
FY16
0
EPS (EUR)
FY18
-0.513
FY17
-1.003
FY16
-0.520
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Winzerlaer Str. 2
JENA     07745

Phone: +493641.508180

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

SPONSORED STORIES